Type 2 diabetes with ASCVD — ABFM Board MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: C — Add a GLP-1 receptor agonist with cardiovascular benefit
In type 2 diabetes with established ASCVD, adding a GLP-1 receptor agonist or SGLT2 inhibitor with proven cardiovascular benefit is recommended independent of baseline A1c considerations. Glyburide is less favored due to hypoglycemia risk.
Reference: ADA Standards of Care in Diabetes, 2026